<DOC>
	<DOC>NCT00541307</DOC>
	<brief_summary>The objective of the study is collect data on the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface in the treatment of chronic Superficial Femoral Artery disease. Device patency at 12 months is the primary endpoint.</brief_summary>
	<brief_title>GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>&gt; lifestyle limiting claudication, rest pain or minor tissue loss&gt; ABI (anklebrachial index) &lt; 0.9 or TBI (toebrachial index) &lt; 0.5 if ABI is &gt;0.9 Stenosis (&gt;50%) or occlusion of native SFA (superficial femoral artery) &gt;5cm Orifice and 1 cm of SFA are patent Popliteal artery is patent at the intercondylar fossa of the femur to the trifurcation At least 1 patent run off vessel Guidewire and deliver system successfully traversed the lesion &gt; Untreated flowlimiting aortoiliac occlusive disease Any previous stenting or surgery in the target vessel Femoral or popliteal aneurysm of target vessel No patent tibial arteries Prior ipsilateral femoral artery bypass Major distal amputation (above the transmetatarsal) in either limb Patients with known sensitivity to Heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
</DOC>